trialsTrialPositive

DREAMM-7

The trial that brought the withdrawn myeloma ADC back, beating a daratumumab-based standard on progression and survival.

DREAMM-7, trial NCT04246047 sponsored by GSK and published in the New England Journal of Medicine in 2024, is the trial that brought the withdrawn myeloma antibody-drug conjugate belantamab mafodotin back, beating a daratumumab-based standard on both progression and survival. It randomised 494 patients with relapsed myeloma after at least one line to belantamab or daratumumab, each with bortezomib and dexamethasone, met its primary progression-free survival endpoint with a large effect and showed a survival benefit in the 2024 update, while ocular events in about eighty percent were managed by dose holds; the drug was re-approved in the United States and European Union in 2025. OnCo links it to multiple myeloma, belantamab mafodotin, bortezomib and Sagar Lonial, and DREAMM-8 is concordant. Whether the eye toxicity is acceptable when bispecifics offer alternatives is the open question.

Setting

Relapsed myeloma after ≥1 line: belantamab-Vd vs Dara-Vd

Phase

Phase 3

Sponsor

GSK

Registry

Headline result

PFS 36.6 vs 13.4 months, HR 0.41; OS HR 0.58.

Started

2020-05-07

Reported

2024

Enrolled

494 enrolled

Replication

DREAMM-8 (belantamab-Pd vs Pom-Vd) concordant, PFS HR 0.52.

Outcomes

In plain words

What these results mean for people, not percentages

494 enrolled

Progression-free survival (median)primarysurrogate endpoint

Median 36.6 vs 13.4 months with Belantamab-Vd compared with Dara-Vd; about 23.2 months longer for half the group.
A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
Put another way, the treated group had about 59 percent lower chance of the event at any given time (hazard ratio 0.41, likely range 0.31 to 0.53).

This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.

Overall survivalsurvival endpoint

The treated group had about 42 percent lower chance of the event at any given time (hazard ratio 0.58).
The absolute difference, how many more people out of 100 were helped, is not reported here.

Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.

Caveats

These results apply to the people the trial enrolled: Relapsed myeloma after ≥1 line: belantamab-Vd vs Dara-Vd. People in a different situation may not see the same effect.

Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.

494 enrolled.

Progression-free survival (median)primary

HR 0.41 (0.31 to 0.53)

Download

Overall survival

HR 0.58 (0.43 to 0.79)

Numbers not yet public.

Endpoint	Arm	n	Value	HR (95% CI)	p	Source
Progression-free survival (median)primary	Belantamab-Vd	243	36.6 months	0.41 (0.31 to 0.53)	-	link
Progression-free survival (median)primary	Dara-Vd	251	13.4 months	0.41 (0.31 to 0.53)	-	link
Overall survival	Belantamab-Vd	-	-	0.58 (0.43 to 0.79)	-	link
Overall survival	Dara-Vd	-	-	0.58 (0.43 to 0.79)	-	link

Replication

DREAMM-8 (belantamab-Pd vs Pom-Vd) concordant, PFS HR 0.52.

Connected

Similar pages

cancers

Multiple myeloma Relapsed or refractory multiple myeloma

technologies

Antibody-drug conjugate (ADC)

drugs

ApprovedADC

Belantamab mafodotin · Blenrep

ApprovedProteasome inhibitor

Bortezomib · Velcade

people